^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | irinotecan (Topoisomerase I inhibitor) + metformin (AMPK activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Final results of a phase II of metformin plus irinotecan for refractory colorectal cancer.
Published date:
05/16/2018
Excerpt:
...40 patients were enrolled, 38 treated. Median age was 56 years (range 22-76), 42% were female, 70% ECOG 1, median body mass index was 27.10 (range 17.10-40.40), 60% harbored KRAS mutated mCRC...The combination of metformin and irinotecan in this heavily pre-treated mCRC population seems safe and promising enough to merit further evaluation in randomized trials.
DOI:
10.1200/JCO.2018.36.15_suppl.e15527
Trial ID:
